Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: An useful salvage therapy

Leukemia and Lymphoma

Volumn 38, Issue 3-4, 2000, Pages 283-293

  Huang, Shang Yi ^a   Yang, Chih Hsin ^a   Chen, Yao Chang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acute promyelocylic leukemia; Arsenic trioxide; Relapse

Indexed keywords

ANTILEUKEMIC AGENT; ARSENIC TRIOXIDE; CHIMERIC PROTEIN; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; CROSS RESISTANCE; DEGENERATIVE DISEASE; DRUG ACCUMULATION; DRUG POTENCY; DRUG TOLERABILITY; FLUID RETENTION; HEART ARRHYTHMIA; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; MUSCLE ATROPHY; NEUROMUSCULAR DISEASE; PARESTHESIA; PRIORITY JOURNAL; RELAPSE; SALVAGE THERAPY; SIDE EFFECT; SKIN TOXICITY;

EID: 0034123033     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009087019     Document Type: Article

References (72)

1. Mitelman, F. (1998) Catalog of chromosome aberrations in cancer, third edition (New York, Alan R. Liss, Inc).
2. Brown, D., Kogan, S., Lagasse, E., Weissman, I., Alcalay, M., Pelicci, P.G., Atwater, S. and Bishop, J.M. (1997) A PML/RAR α transgene initiates murine acute promyelocytic leukemia. Proceedings of the National Academy Society of the USA, 94, 2551-2556.
3. Grignani, F.R., Ferrucci, P.F., Testa, U., Talamo, G., Fagioli, M., Alcalay, M., Mencarelli, A., Grignani, F., Peschle, C., Nicoletti, I. and Pelicci, P.G. (1993) The acute promyelocytic leukemia-specific PML-RAR α fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell, 74, 423-431.
4. de The, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L. and Dejean, A. (1991) The PML/RAR αfusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR α Cell, 66, 675-684.
5. Dyck, J.A., Maul, G.G., Miller, W.H.Jr., Chen, J.D., Kakizuka, A. and Evans, R.M. (1994) A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell, 76, 333-343.
6. Grignani, F., Testa, U., Rogaia, D., Ferrucci, P.F., Samoggia, P., Pinto, A., Aldinucci, D., Gelmetti, V., Fagioli, M., Alcalay, M., Seeler, J., Grignani, F., Nicoletti, I., Peschle, C. and Pelicci, P.G. (1996) Effects on differentiation by the promyelocytic leukemia PML/RAR α protein depend on the fusion of the PML protein dimerization and RAR α DNA binding domains. The EMBO Journal, 15, 4949-4958.
7. Kastner, P., Perez, A., Lutz, Y., Rochete-Egly, C., Gaub, M.P., Durand, B., Lanotte, M., Berger, R. and Chambon, P. (1992) Structures, localization and transcriptional properties of two classes of retinoic acid receptor α fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. The EMBO Journal, 11, 629-642.
8. Le, X.F., Yang, P. and Chang, K.S. (1996) Analysis of the growth and transformation suppressor domains of promyelocytic leukemia gene, PML. Journal of Biological Chemistry, 271, 130-135.
9. Look AT. (1997) Oncogenic transcription factors in the human acute leukemias. Science, 278, 1059-64.
10. Melnick, A. and Licht, J.D. (1999) Deconstructing a disease: RAR α, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood, 93, 3167-3215.
11. Mu, Z.M., Chin, K.V., Liu, J.H., Lozano, G. and Chang, K.S. (1994) PML, a growth suppressor disrupted in acute promyelocytic leukemia. Molecular and Cellular Biology, 14, 6858-6867.
12. Warrell, R.P. Jr., de The, H., Wang, Z. Y. and Degos, L. (1993) Acute promyelocytic leukemia. New England Journal of Medicine, 329, 177-189.
13. Weis, K., Rambaud, S., Lavau, C., Jansen, J., Carvalho, T., Carmo-Fonseca, M., Lamond, A. and Dejean, A. (1994) Retinoic acid regulates aberrant nuclear localization of PML-RAR α in acute promyelocytic leukemia cells. Cell. 76, 345-356.
14. Huang, M.E., Ye, Y.C., Chen, S.R., Chai, J.R., Lu, J.X., Zhao, L., Gu, L.J. and Wang, Z.Y. (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 72, 567-572.
15. Degos, L., Dombret, H., Chomienne, C., Daniel, M.T., Miclea, J.M., Chastang, C., Castaigne, S. and Fenaux, P. (1995) All-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood, 85, 2643-2653.
16. Fenaux, P, Le Deley, M.C., Castaigne, S., Archimbaud, E., Chomienne, C., Link, H., Guerci, A., Duarte, M., Daniel, M.T., Bowen, D., Huebner, G., Bauters, F., Fegueux, N., Fey, M., Sanz, M., Lowenberg, B., Maloisel, F., Auzanneau, G., Sadoun, A., Gardin, C., Bastion, Y., Ganser, A., Jacky, E., Dombret, H., Chastang, C., Degos, L. and the European APL 91 Group (1993) Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood, 82, 3241-3249.
17. Fenaux, P., Chastang, C., Chevret, S., Sanz, M., Dombret, H., Archimbaud, E., Fey, M., Rayon, C., Huguet, F., Sotto, J.J., Gardin, C., Makhoul, P.C., Travade, P., Solary, E., Fegueux, N., Bordessoule, D., Miguel, J.S., Link, H., Desablens, B., Stamatoullas, A., Deconinck, E., Maloisel, F., Castaigne, S., Preudhomme, C. and Degos, L. for the European APL group. (1999) A randomized comparison of all-transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood, 94, 1192-1200.
18. Tallman, M.S., Andersen, J.W., Schiffer, C.A., Appelbaum, F.R., Feusner, J.H., Ogden, A., Shepherd, L., Willman, C., Bloomfield, C.D., Rowe, J.M. and Wiernik, P.H. All-trans retinoic acid in acute promyelocytic leukemia. New England Journal of Medicine, 337, 1021-1028.
19. Huang, S.Y., Chang, C.H., Tang, J.L., Tien, H.F., Kuo, T.L., Huang, S.F., Yao, Y.T., Chou, W.C., Chung, C.Y., Wang, C.H., Shen, M.G. and Chen, Y.C. (1998) Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. British Journal of Haematology, 103, 1092-1095.
20. Shen, Z.X., Chen, G.Q., Ni, J.H., Li, X.S., Xiong, S.M., Qiu, Q.A., Zhu, J., Tang, W., Sun, G.L., Yang, K.Q., Chen, Y., Zhou, L., Fang, Z.W., Wang, Y.T., Ma, J., Zhang, P., Zhang, T.D., Chen, S.J., Chen, Z. and Wang, Z.Y. (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89, 3354-3360.
21. Soignet, S.L., Maslak, P., Wang, Z.G., Jhanwar, S., Calleja, E., Dardashti, L.J., Corso, D., DeBlasio, A., Gabrilove, J., Scheinberg, D.A., Pandolfi, P.P. and Warrell, R.P. Jr. (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New England Journal of Medicine, 339, 1341-8.
22. Sun, H.D., Ma, L., Hu, X.C. and Zhang, T.D. (1992) Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chinese Journal of Integration of Traditional Chinese Medicine and Western Medicine, 12, 170-1. (in Chinese).
23. Zhang, P., Wang, S.Y., Hu, X.H., Shi, F.D., Qiu, F.Q., Hong, G.J., Han, X.Y., Yang, H.F., Sun, Y.Z., Liu, Y.P., Zhao, J. and Jin, Z.J. (1996) Arsenic trioxide treated 72 cases of acute promyelocytic leukaemia. Chinese Journal of Haematology, 17, 58-60. (in Chinese).
24. Ishinishi, N., Tsuchiya, K., Vahter, M. and Fowler, B.A. (1986) Arsenic. Handbook on the Toxicology of Metals (ed. By L. Friberg, G.F. Nordberg and V.B. Vouk), p. 43. Elsevier, Amsterdam.
25. Jiang Su New Medical College. Encyclopedia of Chinese Medicine, pp. 1620-1622. Shanghai, China: Shanghai Scientific Publishing House, 1986.
26. Pershagen, G. The epidemiology of human arsenic exposure. In: Fowler BA, editor. Biological and environmental effects of arsenic. Oxford (U.K.): Elsevier Science Publisher; 1983, P. 199-229.
27. Hei, T.K., Liu, S.X. and Waldren, C. (1998) Mutagenicity of arsenic in mammalian cells: Role of reactive oxygen species. Proceedings of the National Academy Society of the USA, 95, 8103-8107.
28. Lee, T.C., Oshimura, M. and Barrett, J.C. (1985) Comparison of arsenic-induced cell transformation, cytotoxicity, mutation and cytogenetic effects in Syrian hamster embryo cells in culture. Carcinogenesis, 6, 1421-1426.
29. Snow, E.T. (1992) Metal carcinogenesis: mechanistic implications. Pharmacology and Therapy, 53, 31-65.
30. Zhao, C.Q., Young, M.R., Diwan, B.A., Coogan, T.P. and Waalkes, M.P. (1997) Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proceedings of the National Academy of Science of the USA, 94, 10907-10912.
31. Espinoza, E.O., Mann, M.J. and Bleasdell, B. (1995) Arsenic and mercury in traditional Chinese herbal balls. New England Journal of Medicine, 333, 803-804.
32. Niu, C., Yan, H., Sun, H.P., Liu, J.X., Gu, B.W., Su, X.Y., Cao, Q., Waxman, S., Chen, Z., Chen, S J., Shen, Z.X. and Wang, Z.Y. (1998) Treatment of de novo and relapsed acute promyelocytic leukemia patients with arsenic trioxide. Blood, 92 (sup 1), 678a. (abstract).
33. Coco, F.L., Diverio, D., Falini, B., Biondi, A., Nervi, C. and Pelicci, G. (1999) Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood. 94, 12-22.
34. Miller, M. (1998) Scientists explore use of arsenic in therapy. Journal of the National Cancer Institute, 90, 1866-1867.
35. Westervelt, P., Pollock, J., Haug, Ley, T.J. and DiPersio, J.F. (1997) Response and toxicity associated with dose escalation of arsenic trioxide in the treatment of resistant acute promyelocytic leukemia. Blood, 90 (supple 1), 249b. (abstract).
36. Frankel, S.R., Eardley, A., Lauwers, G., Weiss, M. and Warrell, R.P. Jr. (1992) The "retinoic acid syndrome" in acute promyelocytic leukemia. Annals of Internal Medicine, 117, 292-296.
37. Chen, G.Q., Zhu, J., Shi, X.G., Ni, J.H., Zhong, H.J., Si, G.Y., Jin, X.L., Tang, W., Li, X.S., Xong, S.M., Shen, Z.X., Sun, G.L., Ma, J., Zhang, P., Zhang, T.D., Gazin, C., Naoe, T., Chen, S.J., Wang, Z.Y. and Chen, Z. (1996) In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with down regulation of bcl-2 expression and modulation of PML-RAR α /PML proteins. Blood, 88, 1052-1061.
38. Chen, Z.Q., Shi, X.G., Tang, W., Xiong, S.M., Zhu, J., Cai, X., Han, Z.G., Ni, J.H., Shi, G.Y., Jia, P.M., Liu, M.M., He, K.L., Niu, C., Ma, J., Zhang, P., Zhang, T.D., Paul, P., Naoe, T., Kitamura, K., Miller, W., Waxman, S., Wang, Z.Y., de The, H., Chen, S.J. and Chen, Z. (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent effects on APL cells. Blood, 89, 3345-3353.
39. Chen, Z., Wang, Z.Y. and Chen, S.J. (1997) Acute promyelocytic leukemia: Cellular and molecular basis of differentiation and apoptosis. Pharmacology and Therapy, 76, 141-149.
40. Andre, C., Guillemin, M.C., Zhu, J., Koken, M.H.M., Quignon, F., Herve, L., Chelbi-Alix, M.K., Dhumeaux, D., Wang, Z.Y., Degos, L., Chen, Z. and de The, H. (1996) The PML and PML/RAR α domains: From autoimmunity to molecular oncology and from retinoic acid to arsenic. Experimental Cell Research, 229, 253-260.
41. Daniel, M.T., Koken, M., Romagne, O., Barbey, S., Bazarbachi, A., Stadler, M., Guillemin, M.C., Degos, L., Chomienne, C. and de The, H. (1993) PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood, 82, 1858-1867.
42. Koken, M.H.M., Puvion-Dutilleul, F., Guillemin, M.C., Viron, A., Linares-Cruz, G., Stuurman, N., deJong, L., Szostecki, C., Calvo, F., Chomienne, C., Degos, L., Puvion, E. and de The, H. (1994) The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. The EMBO Journal, 13, 1073-1083.
43. Quignon, F., Chen, Z. and deThe, H. (1997). Retinoic acid and arsenic: towards oncogene-targeted treatments of acute promyelocytic leukaemia. Biochimica et Biophysica Acta, 1333, M53-M61.
44. Raelson, J.V., Nervi, C., Rosenauer, A., Benedetti, L., Monczak, Y., Pearson, M., Pelicci, P.G. and Miller, W.H. (1996) The PML/RAR α oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood, 88, 2826-2832.
45. Shao, W., Fanelli, M., Ferrara, F.F., Riccioni, R., Rosenauer, A., Davison, K., Lamph, W.W., Waxman, S., Pelicci, P.G., Lo Coco, F., Avvisati, G., Testa, U., Peschle, C., Cambacorti-Passerini, C., Nervi, C. and Miller, W.H. Jr. (1998) Arsenic trioxide as an inducer of apoptosis and loss of PML-RAR alpha protein in acute promyelocytic leukemia cells. Journal of the National Cancer Institute, 90, 124-33.
46. Zhu, J., Koken, M.H.M., Quignon, F., Chelbi-Alix, M.K., Degos, L., Wang, Z.Y., Chen, Z. and de The, H. (1997) Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proceedings of the National Academy of Science of the USA, 94, 3978-83.
47. Buddy, M.N., Howe, K., Etkin, L.D., Solomon, E. and Freemont, P.S. (1996) PIC-1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukemia. Oncogene, 13, 971-982.
48. Muller, S., Matunis, M.J. and Dejean, A. (1998) Conjugation with the ubiquilin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. The EMBO Journal, 17, 61-70.
49. Sternsdorf, T., Puccetti, E., Jensen, K., Hoelzer, D., Will, H., Ottmann, O.G. and Ruthardt, M. (1999) PIC-1/SUMO-1-modified PML-Retinoic acid receptor α mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Molecular and Cellular Biology, 19, 5170-5178.
50. Dai, J., Jing, Y., Hellinger, N., Weinberg, R. and Waxman, S. (1998) Mechanism of arsenic trioxide induced growth inhibition and apoptosis in malignant cells. Proceedings of the American Association for Cancer Research, 39, 68-69. (abstract).
51. Wang, Z.G., Rivi, R., Delva, L., Konig, A., Scheinberg, D.A., Gambacorti-Passerini, C., Gabrilove, J.L., Warrell, R.P. Jr. and Pandolfi, P.P. (1998) Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RAR a independent manner. Blood, 92, 1497-1504.
52. Larochete, N., Decaudin, D., Jacoto, E., Brenner, C., Marzo, I., Susin, S.A., Zamzami, N., Xie, Z., Reed, J. and Kroemer, G. (1999) Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Experimental Cell Research, 249, 413-421.
53. Chen, Y.C., Lin-Shiau, S.Y. and Lin, J.K. (1998) Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. Journal of Cellular Physiology, 177, 324-333..
54. Jing, Y., Dai, J., Chalmers-Redman, R.M.E., Taton, W.G. and Waxman, S. (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood, 94, 2102-2111.
55. Akao, Y., Nakagawa, Y. and Akiyama, K. (1999) Arsenic trioxide induces apoptosis in neuroblatoma cell lines through the activation of caspase 3 in vitro. FEBS letters, 455, 59-62.
56. Green, D.R. and Reed, J.C. (1998) Mitochondria and apoptosis. Science, 281, 1309-1312.
57. Dai, J., Weinberg, R.S., Waxman, S. and Jing, Y. (1999) Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood, 93, 268-277.
58. Akao, Y, Mizoguchi, H., Kojima, S., Naoe, T., Ohishi, N. and Yagi, K. (1998) Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of bcl-2 protein. British Journal of Haematology, 102, 1055-1060.
59. Zhang, W., Ohnishi, K., Shigeno, K., Fujisawa, S., Naito, K., Nakamura, S., Takeshita, K., Takeshita, A. and Ohno, R. (1998) The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia, 12, 1383-1391.
60. Cavigelli, M., Li, W.W., Lin, A., Su, B., Yoshioka, K. and Karin, M. (1996) The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. The EMBO Journal, 15, 6269-6279.
61. Li, Y.M. and Broome, J.D. (1999) Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Research, 59, 776-780.
62. Gianni, M., Koken, M.H.M., Chelbi-Alix, M.K., Benoit, G., Lanotte, M., Chen, Z. and de The, H. (1998) Combined arsenic and retinoic acid treatment enhances differentiation and upoptosis in arsenic resistant NB4 cells. Blood, 91, 4300-4310.
63. Huang, X.J., Wiernik, P.M., Klein, R.S. and Gallagher, R.E. (1997) Potentiation of arsenic trioxide (As2O3) induced apoptosis by retinoic acid (RA) in RA-sensitive (S) and RA-resistant (R) HL-60 myeloid leukemia cells. Blood, 90 (suppl 1), 329a (abstract).
64. Kizaki, M., Muto, A., Kinjo, K., Ueno, H. and Ikeda, Y. (1998) Application of heavy metal and cytokine for differentiation-inducing therapy in acute promyelocytic leukemia. Journal of the National Cancer Institute, 90, 1906-7.
65. Lallemand-Breitenbach, V., Guillemin, M.C., Janin, A., Daniel, M.T., Degos, L., Kogan, S.C., Bishop, J.M. and de The, H. (1999) Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. Journal of Experimental Medicine, 189, 1043-1052.
66. Bazarbachi, A., El-Sabban, M.E., Nasr, R., Quignon, F., Awaraji, C., Kersual, J., Dianoux, L., Zermati, Y., Haidar, J.H., Hermine, O. and de The, H. (1999) Arsenic trioxide and interferon- α synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood, 93, 278-283.
67. Ishitsuka, K., Hanada, S., Suzuki, S., Utsunomiya, A., Chyuman, Y., Takeuchi, S., Takeshita, T., Shimotakahara, S., Uozumi, K., Makino, T. and Arima, T. (1998) Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. British Journal of Haematology, 103, 721-728.
68. Lu, M., Levin, J., Sulpice, E., Grand, A.S., Alemany, M., Caen, J.P. and Han, Z.C. (1999) Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. Experimental Hematology, 27, 845-852.
69. Rousselot, P., Labaume, S., Marolleau, J.P., Larghero, J., Noguera, M.H., Brouet, J.C. and Fermand, J.P. (1999) Arsenic trioxide and melarsoprol induced apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Research, 59, 1041-1048.
70. Zheng, J., Deng, Y.P., Lin, C., Fu, M., Xiao, P.G. and Wu, M. (1999) Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. International Journal of Cancer, 82, 286-292.
71. Zhu, X.H., Shen, Y.L., Jing, Y.K., Cai, X., Jia, P.M., Huang, Y., Tang, W., Shi, G.Y., Sun, Y.P., Dai, J., Wang, Z.Y., Chen, S.J., Zhang, T.D., Waxman, S., Chen, Z. and Chen, G.Q. (1999) Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. Journal of the National Cancer Institute, 91, 772-778.
72. Yang, C.H., Kuo, M.L., Chen, J.C. and Chen, Y.C. (1999) Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. British Journal of Cancer 81(5), 796-799.